• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

    3/14/24 3:35:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDGL alert in real time by email
    New Drug Application (NDA): 217785
    Company: MADRIGAL PHARMACEUTICALS INC
    • Email

    Products on NDA 217785

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    REZDIFFRA RESMETIROM 60MG TABLET;ORAL Prescription None No No
    REZDIFFRA RESMETIROM 80MG TABLET;ORAL Prescription None No No
    REZDIFFRA RESMETIROM 100MG TABLET;ORAL Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 217785

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    03/14/2024 ORIG-1 Approval Type 1 - New Molecular Entity PRIORITY Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf

    Labels for NDA 217785

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    03/14/2024 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf
    Get the next $MDGL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MDGL

    DatePrice TargetRatingAnalyst
    2/28/2025$236.00 → $422.00Neutral → Buy
    B. Riley Securities
    2/27/2025$400.00 → $405.00Buy
    H.C. Wainwright
    6/28/2024Neutral
    Cantor Fitzgerald
    6/11/2024$382.00Outperform
    Wolfe Research
    4/22/2024$150.00Underperform
    BofA Securities
    3/15/2024$155.00 → $270.00Sell → Neutral
    B. Riley Securities
    3/6/2024$382.00Buy
    Citigroup
    2/26/2024$155.00Neutral → Sell
    B. Riley Securities
    More analyst ratings

    $MDGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp bought $22,516,577 worth of shares (101,792 units at $221.20) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:10:59 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $7,548,616 worth of shares (34,578 units at $218.31) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:09:05 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $12,128,340 worth of shares (64,350 units at $188.47) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      11/21/23 6:15:19 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    SEC Filings

    See more
    • SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

      144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      7/17/25 4:21:23 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

      144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      7/17/25 4:20:56 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

      144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      7/16/25 4:20:19 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

      Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

      3/14/24 3:35:50 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Madrigal Pharmaceuticals upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Madrigal Pharmaceuticals from Neutral to Buy and set a new price target of $422.00 from $236.00 previously

      2/28/25 8:25:11 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Madrigal Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $405.00 from $400.00 previously

      2/27/25 6:40:20 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Madrigal Pharmaceuticals

      Cantor Fitzgerald initiated coverage of Madrigal Pharmaceuticals with a rating of Neutral

      6/28/24 7:43:43 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bate Kenneth was granted 715 shares, increasing direct ownership by 37% to 2,627 units (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      6/24/25 4:45:22 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Levy Richard S was granted 715 shares, increasing direct ownership by 3% to 21,197 units (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      6/24/25 4:42:30 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fouse Jacqualyn A was granted 203 shares, increasing direct ownership by 23% to 1,097 units (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      6/24/25 4:39:48 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

      CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 1, 2025 and July 15, 2025 to a total of 30 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as inducement material to employees' acceptance of employment with the company. The new employees re

      7/16/25 4:05:00 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

      • Provides Protection Through Sept. 2044; Will Be Listed in FDA's Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance covering the FDA-approved use of Rezdiffra™ (resmetirom), the first and only FDA-approved treatment for adults with noncirrhotic MASH (also known as NASH) with moderate to advanced liver fibrosis. The Notice of Allowance includes claims directed to Rezdiffra's commercial weigh

      7/16/25 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

      Positive recommendation based on resmetirom's favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved, resmetirom will be the first medication for people living with MASH in the E.U.   CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of resmetirom

      6/20/25 6:30:32 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

      SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      11/14/24 5:18:50 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Madrigal Pharmaceuticals Inc.

      SC 13G - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      11/14/24 6:30:21 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

      SC 13D/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      3/25/24 4:28:21 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Financials

    Live finance-specific insights

    See more
    • Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

      First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities of $848.1 million at March 31, 2025Company to host conference call today, May 1, 2025, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.

      5/1/25 7:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

      Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a compensated MASH cirrhosis patient population 51% of patients achieved a ≥25% reduction in liver stiffness; a reduction of this magnitude has been associated with reduced progression to end-stage liver diseaseCompany to review topline data during its fourth-quarter and full-year 2024 financial results conference call today, February 26, 2025, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused

      2/26/25 6:30:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

      Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy Completed enrollment of clinical outcomes study of Rezdiffra in patients with compensated NASH/MASH cirrhosisReports cash, cash equivalents, restricted cash and marketable securities of $1.0 billion at September 30, 2024Company to host conference call today, October 31, 2024, at 8 a.m. EDT CONSHOHOCKEN, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic stea

      10/31/24 7:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

      Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn ("Jackie") Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, stated, "I am delighted to welcome Jackie Fouse to Madrigal. Jackie is an accomplished biotech executive who brings more than 30 years of healthcare industry and finance experience

      3/11/25 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

      CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Michael R. Charlton, M.B.B.S., F.R.C.P., as Senior Vice President, Clinical Development, effective October 1, 2024. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, "I am thrilled to have Dr. Charlton joining the Madrigal team; his deep experience as a researcher and clinician treating patients with NASH will bring powerful new insights and ca

      10/1/24 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

      CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Officer and played an instrumental role guiding the company through a period of rapid growth. I feel privileged to be working with Shannon and the other members of our leader

      8/2/24 7:00:21 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care